BiotechTube
Home/Pipeline/ImmCelz™ Platform

ImmCelz™ Platform

Autoimmune Diseases

PreclinicalResearch

Key Facts

Indication
Autoimmune Diseases
Phase
Preclinical
Status
Research
Company
Creative Medical Technology Holdings

About Creative Medical Technology Holdings

Creative Medical Technology Holdings is a US-based regenerative medicine and immunotherapy company with a mission to improve patient lives through innovative autologous cell therapies. Its core strategy leverages two disruptive platforms: the ImmCelz™ Supercharged Autologous Immunotherapy platform for modulating immune disorders and a Rapid Autologous Stem Cell platform for orthopedic and degenerative conditions. Recent achievements include an FDA Orphan Drug Designation for ImmCelz™ in Type 1 Diabetes and a Notice of Allowance for a key patent, positioning the company in sizable markets with a potentially differentiated clinical approach.

View full company profile

Therapeutic Areas

ImmunologyOrthopedicsEndocrinologyUrogynecologyUrology

Other Autoimmune Diseases Drugs

DrugCompanyPhase
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
Gavocabtagene autoleucelAstellasPhase 1/2
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial
I&I PortfolioThird Arc BioPre-clinical
Undisclosed Platform ProgramsZag BioPreclinical
E-602Palleon PharmaceuticalsIND-Enabling
DIASPOT Platform ExpansionDIAsource ImmunoAssaysCommercial & Development
Platform Application for Autoimmune DiseasesALTUCELLPre-clinical/Research